Skip to main content
. 2017 Dec 27;4(2):e000699. doi: 10.1136/openhrt-2017-000699

Table 3.

Management and outcome data of patients with definite endocarditis according to management strategy

Variable Surgery
(n=126)
Medical therapy
(n=45)
Medical therapy
(Surgical turndown)
(n=14)
Pre-ET
(n=74)
Post-ET
(n=63)
P value Pre-ET
(n=21)
Post-ET
(n=24)
P value Pre-ET
(n=6)
Post-ET
(n=8)
P value
Sequelae
 Immunological phenomena 8 (10.8) 9 (14.2) 0.61 3 (14.3) 1 (4.2) 0.33 0 (0) 1 (12.5) 1.00
 Acute stroke 17 (23.0) 15 (23.8) 1.00 4 (19.0) 3 (12.5) 0.69 1 (16.7) 1 (12.5) 1.00
 Other emboli 28 (37.8) 23 (36.5) 1.00 8 (38.1) 6 (25.0) 0.52 2 (33.3) 2 (25.0) 1.00
 Congestive cardiac failure 15 (20.3) 12 (19.0) 1.00 0 (0) 1 (4.2) 1.00 2 (33.3) 2 (25.0) 1.00
 Uncontrolled sepsis 8 (10.8) 17 (27.0) 0.03 7 (33.3) 5 (20.8) 0.50 3 (50.0) 5 (62.5) 1.00
 Valvular abscess 10 (13.5) 10 (15.9) 0.81 0 (0) 0 (0) 1 (16.7) 3 (37.5) 0.58
 Renal failure* 8 (10.8) 6 (9.5) 1.00 2 (9.5) 3 (12.5) 1.00 1 (16.7) 1 (12.5) 1.00
Investigations
 Time to first TTE (days) 8.3±10.9 4.8±6.0 0.02 5.5±14.3 4.3±11.4 0.76 9.3±8.6 5.8±7.5 0.56
 Time to TOE following TTE (days) 4.3±4.3 2.5±1.5 0.005 7.7±1.9 6.7±4.2 0.32 3.7±2.7 2.7±2.7 0.51
 Number of patients undergoing TOE 52 (70.3) 54 (85.7) 0.04 12 (57.1) 18 (75.0) 0.23 5 (83.3) 5 (62.5) 0.58
Management
 Time to IE-specific antibiotics† 3.9±4.0 2.3±3.0 0.01 4.1±3.3 3.1±3.4 0.32 4.5±5.2 2.7±3.9 0.58
 Time to surgery† 7.8±7.3 5.3±4.2 0.004
 Duration of stay 31.4±14.5 24.3±12.6 0.003 26.2±19.1 29.2±19.6 0.61 12.0±2.6 4.3±4.5 0.08
Mortality
 In-hospital 8 (11.4) 6 (9.5) 0.78 6 (28.6) 2 (8.3) 0.12 3 (50.0) 4 (50.0) 1.00
 1 year 14 (18.9) 9 (14.3) 0.51 12 (57.1) 8 (33.3) 0.03 5 (83.3) 5 (62.5) 0.96

Data shown as means±SD or number (percentage).

*Renal failure requiring renal replacement therapy.

†Number of days from suspected infective endocarditis.

ET, endocarditis team; IE, infective endocarditis; TOE, transoesophageal echocardiogram; TTE, transthoracic echocardiogram.